Ascletis Showcases Promising Data from Obesity Drug Candidates at ObesityWeek® 2025

Ascletis Showcases Promising Data from Obesity Drug Candidates at ObesityWeek® 2025

By, Admin 5 November 2025

ASC30 oral tablet achieves up to 6.5% placebo-adjusted weight reduction; injectable formulation demonstrates ultra-long half-life; ASC31 and ASC47 combination outperforms tirzepatide in preclinical studies.

Ascletis Pharma Inc. (HKEX: 1672) announced multiple poster presentations at ObesityWeek® 2025, featuring new clinical and preclinical data from its obesity drug pipeline, including ASC30, ASC31, and ASC47. The data highlight significant progress across the company’s oral, injectable, and combination therapies for chronic weight management.

ASC30 Oral Tablet Shows Up to 6.5% Placebo-Adjusted Weight Reduction

Study: Phase Ib 28-day multiple ascending dose (MAD) trial in participants with obesity

Results:

  • Mean body weight reduction from baseline reached 6.3% at 40 mg (MAD 2 cohort) and 4.3% at 20 mg (MAD 1 cohort), compared with a 0.2% increase in the placebo group.
  • The highest dose (MAD 3, 60 mg) demonstrated a 4.8% mean reduction, with a maximum weight loss of 9.3%.
  • Excluding two outliers, the MAD 3 cohort achieved a 5.9% mean reduction from baseline.
  • No plateau in weight reduction was observed at Day 29.

Safety and Tolerability:

  • No serious adverse events (SAEs) or Grade ≥3 adverse events were reported.
  • Gastrointestinal (GI) side effects were mild to moderate and consistent across cohorts.
  • Laboratory tests, vital signs, ECGs, and hepatic function were within normal limits.

Conclusion: The oral formulation of ASC30 demonstrated clinically meaningful weight loss and a favorable safety profile comparable to or better than other GLP-1 receptor agonists.

ASC30 Subcutaneous Injection Demonstrates Ultra-Long Half-Life

Study: Phase Ib study evaluating ASC30 subcutaneous (SQ) depot formulations

Results:

  • Observed half-life was 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B).
  • Pharmacokinetic data support once-monthly dosing for Injection A and once-quarterly dosing for Injection B.
  • No SAEs or Grade ≥3 adverse events were observed; GI-related AEs were mild to moderate.
  • No hepatic safety concerns were identified.

Conclusion: The ASC30 SQ depot formulations, developed with Ascletis’ Ultra-Long-Acting Platform (ULAP), could simplify obesity treatment by reducing dosing frequency and improving adherence.

ASC31 + ASC47 Combination Outperforms Tirzepatide in Preclinical Studies

Study: Diet-induced obesity (DIO) mouse model

Results:

  • Combination of ASC31 + ASC47 reduced body weight by 44.8%, compared to 19.1% with ASC31 monotherapy — a 134% greater reduction.
  • Combination of ASC47 + tirzepatide led to a 38.1% reduction vs 20.4% for tirzepatide alone — an 87% improvement.
  • The ASC31 + ASC47 combination significantly improved body composition, restoring muscle and fat levels to those of non-obese mice.

Mechanism:

  • ASC31 is a dual GLP-1R/GIPR peptide agonist.
  • ASC47 is a THRβ-selective small molecule agonist designed for adipose tissue targeting.

Leadership Commentary

“These results highlight the strong efficacy and safety profiles of our expanding obesity pipeline,” said Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis. “With ASC30, ASC31, and ASC47, we are advancing both small molecule and peptide-based therapies supported by our AISBDD and ULAP technologies, and we continue to engage with partners globally to meet the growing need for effective obesity treatments.”

About ASC30

ASC30 is an investigational GLP-1 receptor biased small molecule agonist capable of both oral and injectable administration. It is protected under U.S. and global patents through 2044 and developed for once-daily oral or once-monthly to once-quarterly subcutaneous use.

About ASC31

ASC31 is a novel dual GLP-1R and GIPR peptide agonist discovered in-house, demonstrating favorable pharmacokinetics in non-human primates and potent efficacy in obesity models. It is developed using Ascletis’ Ultra-Long-Acting Platform (ULAP) technology.

About ASC47

ASC47 is an adipose-targeted, THRβ-selective small molecule agonist designed for once-monthly subcutaneous injection. It enables high drug concentration in fat tissue while minimizing systemic exposure.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. (HKEX: 1672) is a fully integrated biotechnology company dedicated to developing and commercializing best-in-class therapeutics for metabolic diseases. Using its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis is advancing multiple clinical candidates, including ASC30, ASC31, and ASC47, aimed at improving chronic weight management outcomes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!